Advised by Marco de Lignie from Loyens Loeff, Gilde Healthcare, the European specialist investment firm, has announced the final close of Gilde Healthcare IV, a €250 million later stage and growth capital fund. The new fund, which was oversubscribed, is targeting investments in innovative private scale-up opportunities in medtech, digital health and therapeutics both in Europe and North America.
Gilde Healthcare IV, which closed at its hard cap, is backed by a balanced mix of international investors. Royal Philips (NYSE: PHG, AEX: PHIA) acted as a cornerstone investor, extending the collaboration which started in the previous Gilde Healthcare III fund. Johnson & Johnson Innovation – JJDC, Inc. joined as a new corporate investor in Gilde Healthcare IV. Additional investors include fund-of-funds, sovereign funds such as Danish Growth Fund, endowments, family offices, entrepreneurs and Gilde partners. The European Investment Fund participated in the fund through several of its funding programs including the European Recovery Program and Dutch Venture Initiative II.
Investors have been attracted by Gilde Healthcare’s strong track record. In the last three years, Gilde exited 14 portfolio companies across its healthcare funds realizing significant value for its investors. Amongst the companies that were successfully divested over this period are Definiens, the leading provider of image analysis software for digital pathology; Inovalabs, which markets portable oxygen concentrators for patients with respiratory conditions; ProFibrix, which developed a novel topical hemostatic agent to treat fast bleeding wounds; Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design; Santaris, which develops RNA-targeted drugs and Sapiens, a Dutch neuro-modulation company focused on deep brain stimulation for patients suffering from Parkinson’s disease.